The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 06, 2023
Filed:
Feb. 01, 2022
Applicant:
Obsidian Therapeutics, Inc., Cambridge, MA (US);
Inventors:
Vipin Suri, Belmont, MA (US);
Byron Delabarre, Arlington, MA (US);
Michael N. Gladstone, Cambridge, MA (US);
Celeste Richardson, Brookline, MA (US);
Brian Dolinski, Cambridge, MA (US);
Abhishek Kulkarni, Brookline, MA (US);
Mara Christine Inniss, Beverly, MA (US);
Dexue Sun, Cambridge, MA (US);
Dan Jun Li, Cambridge, MA (US);
Grace Y. Olinger, Cambridge, MA (US);
Scott Francis Heller, Stoughton, MA (US);
Assignee:
OBSIDIAN THERAPEUTICS, INC., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/46 (2006.01); A61P 35/00 (2006.01); A61K 31/4985 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); C07K 14/54 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01); C12N 9/16 (2006.01); A61K 39/00 (2006.01); A61P 37/04 (2006.01); C07K 19/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/465 (2013.01); A61K 31/4985 (2013.01); A61K 35/17 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); A61K 38/2086 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 14/5443 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 14/7155 (2013.01); C07K 16/2803 (2013.01); C12N 9/16 (2013.01); C12Y 301/04035 (2013.01); A61K 2039/505 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01);
Abstract
The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.